These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Patterson LJ; Beal J; Demberg T; Florese RH; Malkevich N; Venzon D; Aldrich K; Richardson E; Kalyanaraman VS; Kalisz I; Lee EM; Montefiori DC; Robey FA; Robert-Guroff M Virology; 2008 May; 374(2):322-37. PubMed ID: 18252262 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. Ourmanov I; Brown CR; Moss B; Carroll M; Wyatt L; Pletneva L; Goldstein S; Venzon D; Hirsch VM J Virol; 2000 Mar; 74(6):2740-51. PubMed ID: 10684290 [TBL] [Abstract][Full Text] [Related]
10. Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. Mossman SP; Pierce CC; Watson AJ; Robertson MN; Montefiori DC; Kuller L; Richardson BA; Bradshaw JD; Munn RJ; Hu SL; Greenberg PD; Benveniste RE; Haigwood NL AIDS Res Hum Retroviruses; 2004 Apr; 20(4):425-34. PubMed ID: 15157361 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. Dale CJ; De Rose R; Stratov I; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Kent SJ J Virol; 2004 Dec; 78(24):13819-28. PubMed ID: 15564490 [TBL] [Abstract][Full Text] [Related]
12. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. Amara RR; Villinger F; Staprans SI; Altman JD; Montefiori DC; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McClure HM; Moss B; Robinson HL J Virol; 2002 Aug; 76(15):7625-31. PubMed ID: 12097576 [TBL] [Abstract][Full Text] [Related]
13. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK J Virol; 2004 Apr; 78(8):3930-40. PubMed ID: 15047809 [TBL] [Abstract][Full Text] [Related]
14. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys. Izumi Y; Ami Y; Matsuo K; Someya K; Sata T; Yamamoto N; Honda M J Virol; 2003 Dec; 77(24):13248-56. PubMed ID: 14645581 [TBL] [Abstract][Full Text] [Related]
15. Better protective effects in rhesus macaques by combining systemic and mucosal application of a dual component vector vaccine after rectal SHIV89.6P challenge compared to systemic vaccination alone. Stolte-Leeb N; Bieler K; Kostler J; Heeney J; Haaft PT; Suh YS; Hunsmann G; Stahl-Hennig C; Wagner R Viral Immunol; 2008 Jun; 21(2):235-46. PubMed ID: 18476770 [TBL] [Abstract][Full Text] [Related]
16. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. Li Y; Cleveland B; Klots I; Travis B; Richardson BA; Anderson D; Montefiori D; Polacino P; Hu SL J Virol; 2008 Jan; 82(2):638-51. PubMed ID: 17959660 [TBL] [Abstract][Full Text] [Related]
17. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Fuller DH; Simpson L; Cole KS; Clements JE; Panicali DL; Montelaro RC; Murphey-Corb M; Haynes JR Immunol Cell Biol; 1997 Aug; 75(4):389-96. PubMed ID: 9315483 [TBL] [Abstract][Full Text] [Related]
18. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. Kwa S; Lai L; Gangadhara S; Siddiqui M; Pillai VB; Labranche C; Yu T; Moss B; Montefiori DC; Robinson HL; Kozlowski PA; Amara RR J Virol; 2014 Sep; 88(17):9579-89. PubMed ID: 24920805 [TBL] [Abstract][Full Text] [Related]
19. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. Xiao P; Zhao J; Patterson LJ; Brocca-Cofano E; Venzon D; Kozlowski PA; Hidajat R; Demberg T; Robert-Guroff M J Virol; 2010 Jul; 84(14):7161-73. PubMed ID: 20444898 [TBL] [Abstract][Full Text] [Related]
20. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]